This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
Services
Translation
Expertise
Specializes in:
Medical: Pharmaceuticals
Medical: Cardiology
Medical (general)
Cosmetics, Beauty
Rates
All accepted currencies
U. S. dollars (usd)
Blue Board entries made by this user
0 entries
Payment methods accepted
Visa, MasterCard, PayPal
Portfolio
Sample translations submitted: 1
English to Russian: Trastuzumab emtansine General field: Medical Detailed field: Medical: Pharmaceuticals
Source text - English Trastuzumab emtansine is a novel antibody−drug conjugate (ADC) that is specifically designed for the treatment of human epidermal growth factor receptor 2 (HER2-positive) malignancies. Trastuzumab emtansine is composed of trastuzumab, a humanized antibody directed against the extracellular region of HER2; DM1, an anti-microtubule agent derived from maytansine; and succinimidyl trans-4-[maleimidomethyl] cyclohexane-1-carboxylate (SMCC), a stable thioether linker reagent used to conjugate DM1 to trastuzumab. This section provides an overview of in vitro characterization, biocomparability assessments, and bioanalytical methods used to characterize trastuzumab emtansine (and other analytes).
The structural complexity of trastuzumab emtansine presents unique analytical challenges. Thus, two key technologies typical for large and small molecule quantification, ligand binding enzyme-linked immunosorbent assay (ELISA), and liquid chromatography tandem mass spectrometry (LC-MS/MS), respectively, were used for trastuzumab emtansine bioanalysis for clinical studies.
Translation - Russian Трастузумаб эмтанзин — инновационный конъюгат антитела и химиопрепарата, разработанный специально для лечения HER2-позитивных злокачественных новообразований. Трастузумаб эмтанзин состоит из трех компонентов: трастузумаба — гуманизированного моноклонального антитела к внеклеточному домену рецептора человеческого эпидермального фактора роста (HER2), ингибитора полимеризации тубулина DM1 (производное мейтанзина) и стабильного тиоэфирного связывающего агента SMCC (сукцинимидил-транс-4-[малеимидометил] циклогексан-1-карбоксилат). Этот раздел предусматривает обзор свойств трастузумаба эмтанзина (и других компонентов) in vitro, оценку биосовместимости и описание биоаналитических методов исследования.
Сложность структуры препарата определяет специфику задач его исследований. Поэтому в клинических испытаниях трастузумаба эмтанзина для количественного анализа макро- и микромолекул применялись два основных метода: твердофазный иммуноферментный анализ (ELISA) и жидкостная хроматография с тандемной масс-спектрометрией (LC-MC/MS).
More
Less
Translation education
Graduate diploma - Protranslation
Experience
Years of experience: 4. Registered at ProZ.com: Jul 2020.
18 years of experience in clinical pharmacology. Currently live in Lincoln City, Oregon. Medical translator from English to Russian and vice versa, specialized in pharmacology and clinical pharmacology: pharmacoepidemiology, toxicology, theoretical pharmacology; posology; pharmacognosy.
Translated from English to Russian Oxford Handbook of Clinical and Laboratory Investigation, articles about clinical trials, computed tomography, and MRI; translated validation reports, certificate of a pharmaceutical product, pathology reports. Translated from Russian to English some descriptions of dietary supplements and cosmetics for the website; translated MRI reports.
Translate an average 1500-2000 words per day depending on the complexity of the text.
Portfolio